FDA reviewing PaxVax's cholera vaccine

PaxVax Inc. (Redwood City, Calif.) said FDA accepted and granted Priority Review to a BLA for Vaxchora ( PXVX0200), a live attenuated vaccine against Vibrio cholerae to prevent cholera infection. Vaxchora's PDUFA date is June 15, 2016.

The company said FDA has identified cholera as a neglected tropical disease under its Priority Review voucher program. ...